Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMC ENTERTAINMENT HOLDINGS, INC. vs Amphastar Pharmaceuticals Inc — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $2.41 (market cap $2.16B), while Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M). The key difference: AMC ENTERTAINMENT HOLDINGS, INC. is far larger — about 2.5× Amphastar Pharmaceuticals Inc's market cap, and AMC ENTERTAINMENT HOLDINGS, INC. pays a 0.11% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMC | AMPH | |
|---|---|---|
Market Cap | $2.16B | $863.95M |
Sector | Media | Health |
52-Week High | $3.15 | $30.81 |
52-Week Low | $0.95 | $16.87 |
Enterprise Value | $9.10B | $1.26B |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMC trades at $2.59, up 0.78% today, with a bullish technical signal and recent earnings beats. The stock is testing the $3.00 resistance level, supported by record box office performance and improved cash flow trends. However, the company remains unprofitable with a net income margin of -10.59% and high debt levels, though valuation ratios like P/S of 0.28 and P/B of 0.64 suggest potential undervaluation.
Outlook is cautiously optimistic due to strong revenue growth and cost discipline, but risks include persistent losses and heavy debt burden. Analyst consensus price target is $3.00, with 32% buy ratings, indicating moderate upside potential if operational improvements continue.
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
